Opposite role of Bax and BCL-2 in the anti-tumoral responses of the immune system

BMC Cancer

Volumn 4, Issue , 2004, Pages

  Bougras, Gwenola ^a   Cartron, Pierre François ^a   Gautier, Fabien ^a   Martin, Stéphane ^b   LeCabellec, Marité ^a   Meflah, Khaled ^a   Gregoire, Marc ^a   Vallette, François M ^a  

^a INSERM   (France)

^b CHU de Nantes   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN BAX; PROTEIN BCL 2; BAX PROTEIN, MOUSE; BAX PROTEIN, RAT; KLRB1 PROTEIN, HUMAN; LECTIN; MEMBRANE ANTIGEN; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY B;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CARCINOGENICITY; CELL PROTECTION; CELL VIABILITY; CONTROLLED STUDY; GENETIC TRANSFECTION; GLIOMA; GLIOMA CELL; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; T LYMPHOCYTE; ANIMAL; CD8+ T LYMPHOCYTE; CELL CLONE; DISEASE COURSE; IMMUNOLOGY; LYMPHOCYTE COUNT; METABOLISM; MOUSE; NUDE MOUSE; TUMOR CELL CULTURE;

ANIMALS; ANTIGENS, SURFACE; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CD8-POSITIVE T-LYMPHOCYTES; CLONE CELLS; DISEASE PROGRESSION; GLIOMA; LECTINS, C-TYPE; LYMPHOCYTE COUNT; MICE; MICE, NUDE; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY B; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 13144271180     PISSN: 14712407     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-2407-4-54     Document Type: Article

References (36)

1. Behin A, Hoang-Xuan K, Carpentier AF, Delattre JY: Primary brain tumours in adults. Lancet 2003, 361:323-31.
2. Le Poole IC, Gerberi MA, Kast WM: Emerging stategies in tumor vaccines. Curr Opin Oncol 2002, 14:641-8.
3. Smyth MJ, Godfrey DI, Trapani JA: A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol 2001, 2: 93-9.
4. Igney FH, Krammer PH: Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2002, 2:277-88.
5. Ferguson TA, Green DR, Griffith TS: Cell death and immune privilege. Int Rev Immunol 2002, 21:153-72.
6. Larsson M, Fonteneau JF, Bhardwaj N: Dendritic cells resurrect antigens from dead cells. Trends in Immunol 2001, 22:141-8.
7. Boisteau O, Gautier F, Cordel S, Henry F, Hartb J, Douillard JY, Vallette FM, Meflah K, Grégoire M: Apoptosis induced by sodium butyrate treatment increases immunogenicity of a rat colon tumor cell line. Apoptosis 1997, 2:403-12.
8. Albert ML, Sauter B, Bardwaj N: Dendritic cells acquire antigen from apoptotic cells and induce class-1-restricted CTLs. Nature 1998, 392:442-3.
9. Ronchetti A, Rovere P, Iezzi G, Galati G, Heltai S, Protti MP, Garancini MP, Manfredi AA, Rugarli C, Bellone M: Immunogenicity of apoptotic cells in vivo: role of antigen load, antigen-presenting cells, and cytokines. J Immunol 1999, 163:130-6.
10. Sauter B, Albert ML, Francisco L, Larsson M, Somersan S, Bhardwaj N: Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med 2000, 191:423-34.
11. Steinman RM, Turley S, Mellman I, Inaba K: The induction of tolerance by dendritic cells that have captured apoptotic cells. J Exp Med 2000, 191:411-6.
12. Trapani JA, Smyth MJ: Functional significance of the perforin/granzyme cell death pathway. Nat Rev Immunol 2002, 2:735-47.
13. Peter ME, Krammer PH: Mechanisms of CD95 (APO-1/Fas)-mediated apoptosis. Curr Opin Immunol 1998, 10: 45-551.
14. Cory S, Adams JM: The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2002, 2: 47-56.
15. Tsujimoto Y, Cossman J, Jaffe E, Croce CM: Involvement of the bcl-2 gene in human follicular lymphoma. Science 1985, 228:1440-3.
16. Ionov Y, Yamamoto H, Krajewski S, Reed JC, Perucho M: Inactivation of the proapoptotic gene Bax confers selective advantage during tumor clonal evolution. Proc Natl Acad Sci U S A 2000, 97:10872-7.
17. Cartron PF, Oliver L, Martin S, Moreau C, LeCabellec MT, Jezequel P, Meflah K, Vallette FM: The expression of a new variant of the pro-apoptotic molecule Bax, Baxpsi, is correlated with an increased survival of glioblastoma multiforme patients. Hum Mol Genet 2002, 11:675-87.
18. Martin S, Toquet C, Oliver L, Cartron PF, Perrin P, Meflah K, Cuillere P, Vallette FM: Expression of bcl-2, bax and bcl-xl in human gliomas: a re-appraisal. J Neurooncol 2001, 52:129-39.
19. Smilowitz HM, Loel DD, Slatkin DN, Micca PL, Nawrocky MM, Youngs K, Tu W, Coderre JA: Long-term immunological memory in the resistance of rats to transplanted 9L gliosarcoma (9LGS) following subcutaneaous immunization with 9GLS cell. J Neuro-Oncol 2000, 46:193-203.
20. Okada H, Attanucci J, Giezeman-Smits KM, Brissette-Storkus C, Fellows WK, Gambatto A, Pollack IF, Pogue-Geile K, Lotze MT, Bozik ME, Chambers WH: Immunization with an antigen identified by cytokine tumor vaccine-assisted SEREX (CAS) suppressed growth of the rat 9L glioma in vivo. Cancer Res 2001, 61:2625-31.
21. Cartron PF, Juin P, Oliver L, Martin S, Meflah K, Vallette FM: Non-redundant role of Bax and Bak in bid-mediated apoptosis. Mol Cell Biol 2003, 23:4701-12.
22. Vairo G, Soos TJ, Upton TM, Zalvide J, DeCaprio JA, Ewen ME, Koff A, Adams JM: Bcl-2 retards cell cycle entry through p27(Kip1), pRB relative p130, and altered E2F regulation. Mol Cell Biol 2000, 20:4745-53.
23. Clarke TM, Pilkington GJ: Production and evaluation of syngenic antibodies showing specificity for the A15A5 transplantable rat glioma. Neuropathol Appl Neurobiol 1995, 21:130-135.
24. Henry F, Boisteau O, Bretaudeau L, Lieubeau B, Meflah K, Grégoire M: Antigen-presenting cells thath phagocytose apoptotic tumor-derived cells are potent tumor vaccines. Cancer Res 1999, 59:3329-32.
25. Parney IF, Hao C, Petruk KC: Glioma immunology and immunotherapy. Neurosurgery 2000, 46:778-92.
26. Yu JS, Wheeler CJ, Zeltzer PM, Ying H, Finger DN, Lee PK, Yong WH, Incardona F, Thompson RC, Riedinger MS, Zhang W, Prins RM, Black KL: Vaccination of malignant glioma patients with peptidepulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 2001, 61:842-7.
27. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000, 100:57-70.
28. Cartron PF, Juin P, Oliver L, Meflah K, Vallette FM: Impact of the proapoptotic proteins bax and bak in tumor progression and response to treatment. Expert Rev Anticancer Ther 2003, 3: 63-70.
29. Lowe SW, Lin AW: Apoptosis in cancer. Carcinogenesis 2000, 21:485-495.
30. Neumann H, Medana IM, Bauer J, Lassmann H: Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases. Trends Neurosci 2002, 25:313-9.
31. Sampson JH, Archer GE, Ashley DM, Fuchs HE, Hale L, Dranoff G, Bigner DD: Subcutaneous vaccination with irradiated cytokine-producing tumor cells stimulates CD8+ cell mediated-immunity against tumors located in the "immunological priviledge" central immune sytem. Proc Natl Acad Sci USA 1996, 91:10399-404.
32. Oliver L, Tremblais K, Guriec N, Martin S, Meflah K, Menanteau J, Vallette FM: Influence of bcl-2-related proteins on matrix metalloproteinase expression in a rat glioma cell line. Biochem Biophys Res Commun 2000, 273:411-6.
33. Kuriyama H, Lamborn KR, O'Fallon JR, Iturria N, Sebo T, Schaefer PL, Scheithauer BW, Buckner JC, Kuriyama N, Jenkins RB, Israel MA: Pronostic significance of an apoptotic index and apoptosis/proliferation ratio for patients with high grade astrocytomas. Neuro-Oncol 2002, 4:179-86.
34. Roth W, Weller M: Chemotherapy and immunotherapy of malignant glioma: molecular mechanisms and clinical perspectives. Cell Mol Life Sci 1999, 56:481-506.
35. McIlroy D, Cartron PF, Tuffery P, Dudoit Y, Samri A, Autran B, Vallette FM, Debre P, Theodorou I: A triple-mutated allele of granzyme B incapable of inducing apoptosis. Proc Natl Acad Sci U S A 2003, 100:2562-7.
36. Bonnotte B, Favre N, Moutet M, Fromentin A, Solary E, Martin M, Martin F: BCL-2-mediated inhibition of apoptosis prevents immunogenicity and restores tumorigenicity of spontaneously regressive tumors. J Immunol 1998, 161:1433-8.